Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects

References

• DaviesMJ, D’AlessioDA, FradkinJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701.30291106
   PubMed Web of Science ®Google Scholar
• ZhengY, LeySH, HuFB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.29219149
   PubMed Web of Science ®Google Scholar
• JeonJY, LeeSJ, LeeS, et al. Failure of monotherapy in clinical practice in patients with type 2 diabetes: the Korean National Diabetes Program. J Diabetes Investig. 2018;9(5):1144–1152.
   PubMed Web of Science ®Google Scholar
• QaseemA, BarryMJ, HumphreyLL, ForcieaMA; Clinical Guidelines Committee of the American College of P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279–290. doi:10.7326/M16-186028055075
   PubMed Web of Science ®Google Scholar
• ThornberryNA, GallwitzB. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–486.19748065
   PubMed Web of Science ®Google Scholar
• NauckMA, MeierJJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(S1):5–21. doi:10.1111/dom.1312929364588
   PubMed Web of Science ®Google Scholar
• McCormackPL. Evogliptin: first global approval. Drugs. 2015;75(17):2045–2049. doi:10.1007/s40265-015-0496-526541763
   PubMed Web of Science ®Google Scholar
• GuN, ParkMK, KimT-E, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709. doi:10.2147/DDDT.S65678
   PubMed Web of Science ®Google Scholar
• JeongHU, KimJH, LeeDY, ShimHJ, LeeHS. In vitro metabolic pathways of the new anti-diabetic drug evogliptin in human liver preparations. Molecules. 2015;20(12):21802–21815. doi:10.3390/molecules20121980826690104
   PubMed Web of Science ®Google Scholar
• OhES, ChoiC, KimCO, et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. J Clin Pharm Ther. 2017;42(6):689–694.28806472
   PubMed Web of Science ®Google Scholar
• MFDS approval of a new, domestically-developed, oral antihyperglycaemic agent [media release]. Ministry of Food and Drug Safety; 2015 Available from:https://www.mfds.go.kr/brd/m_99/view.do?seq=28999. Accessed 212, 2020.
   Google Scholar
• DevchandPR, LiuT, AltmanRB, FitzGeraldGA, SchadtEE. The pioglitazone trek via human PPAR Gamma: from discovery to a medicine at the FDA and beyond. Front Pharmacol. 2018;9:1093.30337873
   PubMed Web of Science ®Google Scholar
• America TP. ACTOS Package Insert; 2011.
   Google Scholar
• KajosaariLI, JaakkolaT, NeuvonenPJ, BackmanJT. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol. 2006;62(3):217–223. doi:10.1007/s00228-005-0093-816447051
   PubMed Web of Science ®Google Scholar
• WangB, SunY, SangY, LiuX, LiangJ. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine. 2018;97(46).
   Web of Science ®Google Scholar
• SripalakitP, MaphantaS, NeamhomP, SaraphanchotiwitthayaA, PolnokS, YokubolD. Comparative study on the bioequivalence of two formulations of pioglitazone tablet in healthy Thai male volunteers. Drug Dev Ind Pharm. 2007;33(12):1362–1368.18097810
   PubMed Web of Science ®Google Scholar
• Food U, Administration D. Clinical drug interaction studies—study design, data analysis, and clinical implications guidance for industry. FDA; 2017 Available from:https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf. Accessed 1012, 2020.
   Google Scholar
• KimHJ, KwakWY, MinJP, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2011;21(12):3809–3812. doi:10.1016/j.bmcl.2011.04.02921570283
   PubMed Web of Science ®Google Scholar
• RosenstockJ, InzucchiSE, SeufertJ, FleckPR, WilsonCA, MekkiQ. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–2408. doi:10.2337/dc10-015920724648
   PubMed Web of Science ®Google Scholar
• RosenstockJ, KimSW, BaronMA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(2):175–185. doi:10.1111/j.1463-1326.2006.00698.x17300593
   PubMed Web of Science ®Google Scholar
• BajajM, GilmanR, PatelS, Kempthorne-RawsonJ, Lewis-D’AgostinoD, WoerleHJ. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study. Diabet Med. 2014;31(12):1505–1514. doi:10.1111/dme.1249524824197
   PubMed Web of Science ®Google Scholar
• BarnettA. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60(11):1454–1470. doi:10.1111/j.1742-1241.2006.01178.x17073841
   PubMed Web of Science ®Google Scholar
• HermanGA, StevensC, Van DyckK, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688. doi:10.1016/j.clpt.2005.09.00216338283
   PubMed Web of Science ®Google Scholar
• NewsholmeP, CruzatVF, KeaneKN, CarlessiR, de BittencourtPIH Jr. Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem J. 2016;473(24):4527–4550.27941030
   PubMed Web of Science ®Google Scholar
• Burgos-MorónE, Abad-JiménezZ, Martínez de MarañónA, et al. Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med. 2019;8(9):1385. doi:10.3390/jcm8091385
   PubMed Web of Science ®Google Scholar
• GămanM-A, EpîngeacME, DiaconuCC, GămanAM. Evaluation of oxidative stress levels in obesity and diabetes by the free oxygen radical test and free oxygen radical defence assays and correlations with anthropometric and laboratory parameters. World J Diabetes. 2020;11(5):193. doi:10.4239/wjd.v11.i5.19332477455
   PubMed Web of Science ®Google Scholar
• DobricăE-C, GămanM-A, CozmaM-A, BratuOG, Pantea StoianA, DiaconuCC. Polypharmacy in type 2 diabetes mellitus: insights from an internal medicine department. Medicina. 2019;55(8):436. doi:10.3390/medicina55080436
   PubMed Web of Science ®Google Scholar
• CercatoC, FelícioJS, RussoLAT, et al. Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study. Diabetol Metab Syndr. 2019;11(1):1–8. doi:10.1186/s13098-019-0505-z30622652
   PubMed Web of Science ®Google Scholar
• RougheadEE, ChanEW, ChoiN-K, et al. Variation in association between thiazolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six countries. Drug Saf. 2015;38(9):823–831. doi:10.1007/s40264-015-0318-426216600
   PubMed Web of Science ®Google Scholar